NCX 1022

Drug Profile

NCX 1022

Alternative Names: NCX-1022; Nitric oxide-donating derivative of hydrocortisone - NicOx; NO-hydrocortisone

Latest Information Update: 10 Oct 2007

Price : $50

At a glance

  • Originator NicOx
  • Developer Ferrer; NicOx
  • Class Antipsoriatics; Glucocorticoids; Pregnenediones
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Psoriasis; Seborrhoeic dermatitis

Most Recent Events

  • 10 Oct 2007 No development reported - Phase-I for Psoriasis in France (Topical)
  • 10 Oct 2007 No development reported - Phase-II for Seborrhoeic dermatitis in France (Topical)
  • 15 Sep 2005 NicOx expands its existing collaboration with Ferrer Grupo International for the research, development and marketing of nitric oxide-donating corticosteroids for dermatological indications, including NCX 1022
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top